Abstract
The endocrine therapy (ET) has established itself as the basis for drug treatment in MLBC due to its high efficiency and low toxicity. Aromatase inhibitors (AI) are initial therapy in the most cases. However, a third of them have a progression of the disease due to primary or acquired resistance.The role of ESR1 mutations is actively discussed as an early and practically achievable (especially when repeat biopsies are impossible) marker for predicting the development of insensitivity to standard ET.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
